Anavex Life Sciences (AVXL)

• Market cap: $780M
• 1 day: -9.26%
• 5 days: -16.42%
• 1 month: 0.00%
• 3 months: 67.15%
• 6 months: 55.57%
• Year to date: -24.20%
• 1 year: 52.23%
• 5 years: 179.09%
• 10 years: -2.54%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Employees: 40

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

53% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 30

33% more capital invested

Capital invested by funds: $115M [Q2] → $153M (+$37.9M) [Q3]

28% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 18

2% more funds holding

Funds holding: 140 [Q2] → 143 (+3) [Q3]

2% more call options, than puts

Call options by funds: $4.89M | Put options by funds: $4.79M

0.39% less ownership

Funds ownership: 32.24% [Q2] → 31.85% (-0.39%) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $42 356% upside
• Avg. target: $45 385% upside
• High target: $46 399% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 39% 1-year accuracy 74 / 190 met price target	399% upside $46	Buy Maintained	15 Jan 2025
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 119 / 312 met price target	356% upside $42	Buy Maintained	26 Dec 2024
EF Hutton Jason Kolbert 39% 1-year accuracy 74 / 190 met price target	399% upside $46	Buy Maintained	31 Oct 2024